Sotagliflozin is a drug with dual inhibitory effects on sodium-dependent glucose transporters (SGLT) 1 and 2. Inhibition of SGLT1 can inhibit glucose and galactose absorption in the digestive tract, and inhibition of SLGT2 can reduce glucose reabsorption in the renal tubules. Sotagliflozin has been shown to be effective in the treatment of type 2 diabetes mellitus. In recent years, it has shown great potential in cardiovascular diseases. Soglitazone can reduce adverse cardiovascular events in type 2 diabetes patients with cardiovascular risk factors. This article summarized the research on the application of sotagliflozin in diabetes mellitus complicated with cardiovascular diseases at home and abroad in recent years, in order to provide guidance for the further application of sotagliflozin in cardiovascular diseases.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |